Wednesday, November 6, 2013

Levosimendan Going To Drive OXBT Shares Higher

Levosimendan is a cardiac medication proven to be effective in reducing mortality among patients with reduced heart function as they were having surgery.  Levosimendan is a calcium sensitizer that can be administered intravenously (IV) to patients with acute decompensated congestive heart failure (CHF).  The drug helps dilate vessels, increasing heart muscle contractility without increasing the oxygen consumption requirement.

Oxygen Biotherapeutics Inc. NASDAQ stock OXBT signed a definitive agreement in October 2013 for exclusive rights to develop and market Levosimendan in North America.  This transaction between OXBT and Phyxius Pharma Inc. is valued at approximately 4.8 million in stock.

Should the drug Levosimendan be successfully commercialized one would expect OXBT share (7.70) value to rise significantly.  Levosimendan  can produce a much appreciated effect for the patient during cardiac surgery.  Home Care Path encourages readers to follow OXBT and see if  the drug Levosimendan can improve share performance.


             WATCH  FOR  US

 
 

 App  http://appsmakerstore.com/appim/j6kcdet8xvwk4s


Blog  http://homecarepathseniorcare.blogspot.com/

 Home Care Path  www.homecarepath.com and the Wisconsin PATH ALONG model deliver an advanced supportive care service.  Helping seniors in the home, with clinic visits, at the hospital, nursing home and assisted living facility.  Helping seniors downsize with a move in to an adult child's home. 2013 rates are 20.00 per hour.  Simply call 608-432-4286 to schedule an interview.  We can be there when you are working.  We accept long term care insurance.  Services can be tax deductible.  Help with resources and the transition from private payment to public funded programming.  Valuing home and human life
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)